



Title:


## Certificate of Analysis (CoA)

**Date:** 5/12/2026  
**Date Tested:** 5/8/2026  
**Customer:** VeriPure  
**Testing material:** Blind\_Study\_3  
**Lot Number:** unspecified  
**BT Sample ID:** 005000039920341  
**Labeled Peptide Content/Potency:** Unknown  
**Storage:** R.T.  
**Visual Description:** Small clear vial: purple sample, holographic label, silver crimp, dark blue plastic cap.  
**Labeled as:** Blind\_Study\_3  
**Manufacturer:** N/A  
**Testing Purpose:** FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.



Test	Method	Specification	Result
General Appearance	USP <630>	purple powder	purple powder
Mass	USP <41>	As recorded	134.2 mg
FTIR Identification and Composition Analysis	USP <197A>	Sample spectrum should confirm the content of peptide via characteristic bands	FTIR sample spectrum confirms the presence of KLOW with addition of excipient(s)/fillers.
HPLC Purity of Peptide Assay	USP <621>	Specifications: $\geq 98\%$	99.7 %
HPLC Potency Assay	USP <621>	Specifications: Blind Study	GHK-CU 48.4 mg KPV 13.2 mg BPC-157 9.1 mg TB-500 10.7 mg
Peptide-to-Excipients Ratio	USP <1151>	Recommended ratios of (1:2) to (1:10) for (peptide: excipients)	81.5 : 52.7 mg (1:0.6)

The results of the CoA relate only to the item(s) tested and applied to the sample as received.



Andrea Castro, AS  
Scientist-II  
BTLabs




Verna Zheng, AS  
Scientist-II  
BTLabs



Title:

## Certificate of Analysis (CoA)

### FTIR ID and Composition Analysis: Blind Study 3 Lot unspecified



### HPLC Purity and Potency Assay @ 220 nm: Blind Study 3 Lot unspecified



#### **Blind Study 3 Lot unspecified @ 220 nm**

Peak #:	Retention Time (min)	Area (mAU*s)
1	1.596	16161.6
2	1.818	4246.1
3	3.825	4023.2
4	4.18	2649.5